InsidersTradesSigma
Nuvation Bio Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Nuvation Bio Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Nuvation Bio Inc. has logged 30 reports. Market capitalisation: €3.1bn. The latest transaction was reported on 6 May 2025 (Levée d'options). Among the most active insiders: Omega Fund V, L.P.. All data is free.
30
Insider Decl.
0
Thresholds
€17m
11 ops.
Buy Volume
€100m
12 ops.
Sell Volume
49Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 19,702 of 25,750 companies
33.4
score / 100
Value16
Quality51
FCF yld-9.3%
Earn yld-11%
EV/EBITDA·
ROE-40%
Gross mgn85%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 6 May 2025
Declarations30 total
20,000 shares@ US$1.94100.0% of flowClass A Common StockSEC:0001415889-25-012096:0
200,000 shares@ US$1.6636100.0% of flowClass A Common StockSEC:0001415889-25-010446:0
Ideal exit: 30 Dec 2025 (T+270)
1,100 shares@ US$1.665597.8% of flowClass A Common StockSEC:0001415889-25-009908:0
Ideal exit: 27 Dec 2025 (T+270)
56,361 shares@ US$2.89100.0% of flowClass A Common StockSEC:0001415889-24-026701:0
19 shares@ US$2.1952.2% of flowClass A Common StockSEC:0001415889-24-024982:0
Ideal exit: 5 Jul 2025 (T+270)
2,543,600 sharesClass A Common StockSEC:0001415889-24-022940:0
967,100 sharesClass A Common StockSEC:0001415889-24-022899:0
277,895 shares@ US$2.9775.9% of flowClass A Common StockSEC:0001415889-24-018231:0
Ideal exit: 22 Mar 2025 (T+270)
87,715 shares@ US$2.9924.1% of flowClass A Common StockSEC:0001415889-24-018162:0
Ideal exit: 17 Mar 2025 (T+270)
172,189 shares@ US$2.9043100.0% of flowClass A Common StockSEC:0001415889-24-016680:0
Ideal exit: 8 Mar 2025 (T+270)
293,203 shares@ US$1.74100.0% of flowClass A Common StockSEC:0001415889-24-014769:0
1,378,989 shares0Class A Common StockSEC:0001415889-24-010720:0
314,106 sharesClass A Common StockSEC:0001415889-24-010738:0
5,143,000 shares@ US$1.256240.8% of flowClass A Common StockSEC:0000935836-23-000621:0
Ideal exit: 15 Jun 2024 (T+270)
5,143,000 shares@ US$1.256240.9% of flowClass A Common StockSEC:0000935836-23-000619:0
Ideal exit: 16 Nov 2023 (T+270)
368,408 shares0Class A Common StockSEC:0001209191-23-014890:0
75,041 shares@ US$1.8535100.0% of flowClass A Common StockSEC:0001209191-22-059756:0
Ideal exit: 27 Aug 2023 (T+270)
2,500,000 shares@ US$5.600.41% mcap12.9% of flowCommon StockSEC:0000899243-22-014279:0
500,000 shares@ US$10.0710.3% of flowCommon StockSEC:0000899243-21-048798
500,000 shares@ US$10.070.14% mcap4.5% of flowCommon StockSEC:0000899243-21-048798:0
1,400,000 shares@ US$9.800.39% mcap12.2% of flowCommon StockSEC:0000899243-21-047514:0
1,400,000 shares@ US$9.8027.9% of flowCommon StockSEC:0000899243-21-047514
151,544 shares@ US$10.450.043% mcap50.0% of flowClass A Common StockSEC:0001567619-21-021329:0
Ideal exit: 26 Dec 2021 (T+270)
151,544 shares@ US$10.45100.0% of flowClass A Common StockSEC:0001567619-21-021329
Ideal exit: 26 Dec 2021 (T+270)
295,000 shares@ US$9.760.082% mcap2.6% of flowCommon StockSEC:0000899243-21-046103:0
25 of 30 declarations
About Nuvation Bio Inc.
Nuvation Bio Inc. is a United States-based biopharmaceutical company listed on the NYSE/NASDAQ market, with corporate headquarters in New York, United States. Founded in 2018 by David Hung, M.D., a well-known biopharma executive and former founder of Medivation, the company was built around a strategy of developing and acquiring differentiated oncology assets aimed at areas of high unmet medical need. Its model is more focused than that of a broad diversified pharma company: Nuvation Bio is positioning itself as a specialized oncology player, relying on scientifically distinct programs with the potential to create both clinical and commercial value. The company’s core business centers on a small but strategically important pipeline. Its lead asset is taletrectinib, marketed in the United States as IBTROZI for certain advanced ROS1-positive non-small cell lung cancer patients. This product is the key inflection point in the company’s evolution, because it moved Nuvation Bio from a development-stage biotech toward a commercial-stage company in 2025. Beyond IBTROZI, the pipeline includes safusidenib, a brain-penetrant IDH1 inhibitor, NUV-1511, an innovative drug-drug conjugate designed for targeted cancer treatment, and NUV-868, a BD2-selective BET inhibitor. Together, these programs reflect a research strategy centered on mechanistically differentiated oncology assets rather than a large number of early-stage bets. From a competitive standpoint, Nuvation Bio operates in one of the most challenging and crowded segments of healthcare. It competes with both specialized biotech companies and larger pharmaceutical firms with established oncology franchises. Its relative advantage lies in the scientific profile of its programs, the experience of its management team, and its focus on high-need therapeutic niches. At the same time, as with most mid-cap biotech names, the company remains exposed to clinical, regulatory, commercialization, and financing risk, and its valuation will continue to depend heavily on execution and data readouts. Recent developments have strengthened the investment case around the lead asset. In 2025, the FDA approved IBTROZI for advanced ROS1-positive lung cancer, creating the company’s first commercial revenue stream. In 2026, Nuvation Bio announced FDA acceptance of a supplemental filing intended to update efficacy information on the label, and the drug was added to NCCN guideline recommendations for certain central nervous system cancer-related use cases. The company also signed an exclusive licensing agreement with Eisai for Europe and additional territories outside the United States, China, and Japan, expanding the potential geographic footprint of taletrectinib. For international investors, Nuvation Bio is best viewed as an oncology transition story: a U.S.-listed biotech with an emerging commercial product, an expanding geographic opportunity, and a pipeline that still provides meaningful upside optionality.
